Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that it has been issued U.S. Patent Number 8,377,674 (“the ‘674 Patent”) by the United States Patent Office. The issued claims relate to methods used for producing genetically-modified cells utilizing proprietary genome editing tools. These tools and resulting cells are made possible via Precision’s next-generation genome engineering technologies, known collectively as the Directed Nuclease Editor or DNE.
“Our team is thrilled that the U.S. Patent Office has granted patent protection to this critical contribution to the genome engineering field,” stated Jeff Smith, co-inventor and Precision BioSciences’ Chief Scientific Officer. “This newly issued patent provides the company with broad claims to many of the methods used by DNE nucleases to modify eukaryotic cells.”
Precision’s DNE technology allows for highly precise gene editing with engineered nucleases, a technique named Method of the Year by Nature Methods. The ‘674 Patent greatly strengthens the Company’s ability to protect and capitalize on cells modified with DNE genome editing nucleases. Precision now controls a growing patent estate consisting of thirteen issued genome engineering patents in the U.S. and one in Europe.